A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC

PHASE3CompletedINTERVENTIONAL
Enrollment

339

Participants

Timeline

Start Date

February 21, 2013

Primary Completion Date

June 21, 2017

Study Completion Date

June 21, 2017

Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
OTHER

Conventional Transarterial Chemoembolization (cTACE)

"Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~ 1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"

Trial Locations (1)

Unknown

National Cancer Center, Korea, Seoul

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV

NCT01829035 - A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC | Biotech Hunter | Biotech Hunter